Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26723127 | 0.96 | FAAH (0.48) | FAAHEPHX2CNR1CNR2DGKA | |
| SCHEMBL25875656 | 0.92 | CYP3A4 (0.45) | — | |
| SCHEMBL26723166 | 0.91 | ALDH1A1 (0.50) | FAAHEPHX2CNR1CNR2 | |
| SCHEMBL16826149 | 0.88 | CYP3A4 (0.49) | — | |
| SCHEMBL25875229 | 0.88 | PRSS1 (0.48) | — | |
| SCHEMBL16826374 | 0.88 | CYP3A4 (0.49) | — | |
| SCHEMBL25869894 | 0.88 | FAAH (0.52) | FAAHCNR1CNR2DGKAMGLL | |
| SCHEMBL25644954 | 0.85 | PRSS1 (0.46) | — | |
| SCHEMBL18195653 | 0.85 | CYP3A4 (0.50) | DGKA | |
| SCHEMBL31647809 | 0.84 | CYP3A4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | FAAH 1683/4885EPHX2 2210/4885CNR1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.